Catalogue

Pdf

My visitor profile

Apmonia Therapeutics is a biotechnology company dedicated to developing therapeutics strategies towards cancer. We are developing a first-in-class pipeline of next-generation peptide-based therapies targeting the tumor microenvironment to improve the lives of patients with cancer.

Using molecular modelling (i.e. ligand:protein and protein:protein docking simulations, as well as molecular dynamics simulations) and our vast knowledge of matrix biology and oncology, we are developing a portfolio of proprietary first-in-class peptide-based therapies targeting the tumour extracellular matrix (ECM) molecules. After years of research on cancer-stroma interactions, we identified several proteins which are overexpressed in different types of solid tumours, converting them into potential targets for anticancer treatments. By producing peptides that selectively target ECM components, we can regulate the interplay between cancer and stromal cells within the TME, disrupting tumoural activity. In addition, by addressing stroma signals, we may overcome the resistance to therapeutics enabled by the ECM. Finally, our solution also opens the door to synergistic approaches with other therapeutic agents (e.g., ICIs, mAbs, PARP inhibitors).

Albin JEANNE

CEO

Out-licensing / collaboration opportunities, Financing / investment opportunities

Apmonia Therapeutics is aiming to raise €20m in Series A from Venture capital / Corporate venture to support the first clinical phases (Phase 1/2a) as well as lifecycle management activities and R&D activities on new products/new targets (AP-02 to AP-05). This funding round will also cover the fixed costs over the period and time required to exploit the results of FiH trial for commercial development (out-licensing).